Sayak Choudhury1, Archi Agrawal1, Gouri Pantvaidya2, Sneha Shah1, Nilendu Purandare1, Ameya Puranik1, Venkatesh Rangarajan3. 1. Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhaba National Institute (HBNI), E. Borges Road, Parel, Mumbai, 400 012, India. 2. Department of Surgical Oncology, Tata Memorial Hospital, Homi Bhaba National Institute (HBNI), E. Borges Road, Parel, Mumbai, 400 012, India. 3. Department of Nuclear Medicine and Molecular Imaging, Tata Memorial Hospital, Homi Bhaba National Institute (HBNI), E. Borges Road, Parel, Mumbai, 400 012, India. drvrangarajan@gmail.com.
Abstract
The 2015 American Thyroid Association (ATA) guideline have suggested modifications in the risk stratification (RS) for differentiated thyroid cancer (DTC) patients, introduced the concept of dynamic risk stratification (DRS) and redefined the role of radioactive iodine (RAI) in treatment algorithm. The aim of this retrospective audit was to assess the practical implications of these modifications in management of DTC. METHODS: A total of 138 DTC patients were stratified according to ATA 2009 and 2015 guidelines into low (LR), intermediate (IR) and high (HR) risk groups. Change in RS and in intention of RAI use was calculated. Deviation in administered RAI dosage from the guidelines was assessed. 1-year follow-up data was audited to assess how the DRS modified the initial risk estimate. RESULTS: A total of 11.6% of patients changed their RS categories in 2015 guidelines. A total of 10.1% got upstaged to HR, and 1.4% got downstaged to LR. In 2.17% of patients' intention of RAI use changed to remnant ablation from adjuvant therapy and 65% of the LR patients won't require any RAI therapy. A total of 26.7% of patients had received significantly more RAI dosage according to ATA 2015. At 1-year follow-up according to DRS 84% of LR, 75% of IR and 44% of HR patients showed excellent response (ER). CONCLUSION: More patients changed RS to HR than to LR. Intention of RAI use changed in only a small number of patients. Significantly higher dosage of RAI is being administered to patients in current practice. The effect of DRS in modifying the initial RS was most prominent in IR, with most showing ER to initial therapy.
The 2015 American Thyroid Association (ATA) guideline have suggested modifications in the risk stratification (RS) for differentiated thyroid cancer (DTC) patients, introduced the concept of dynamic risk stratification (DRS) and redefined the role of radioactive iodine (RAI) in treatment algorithm. The aim of this retrospective audit was to assess the practical implications of these modifications in management of DTC. METHODS: A total of 138 DTC patients were stratified according to ATA 2009 and 2015 guidelines into low (LR), intermediate (IR) and high (HR) risk groups. Change in RS and in intention of RAI use was calculated. Deviation in administered RAI dosage from the guidelines was assessed. 1-year follow-up data was audited to assess how the DRS modified the initial risk estimate. RESULTS: A total of 11.6% of patients changed their RS categories in 2015 guidelines. A total of 10.1% got upstaged to HR, and 1.4% got downstaged to LR. In 2.17% of patients' intention of RAI use changed to remnant ablation from adjuvant therapy and 65% of the LR patients won't require any RAI therapy. A total of 26.7% of patients had received significantly more RAI dosage according to ATA 2015. At 1-year follow-up according to DRS 84% of LR, 75% of IR and 44% of HR patients showed excellent response (ER). CONCLUSION: More patients changed RS to HR than to LR. Intention of RAI use changed in only a small number of patients. Significantly higher dosage of RAI is being administered to patients in current practice. The effect of DRS in modifying the initial RS was most prominent in IR, with most showing ER to initial therapy.
Authors: R Michael Tuttle; Hernan Tala; Jatin Shah; Rebecca Leboeuf; Ronald Ghossein; Mithat Gonen; Matvey Brokhin; Gal Omry; James A Fagin; Ashok Shaha Journal: Thyroid Date: 2010-10-29 Impact factor: 6.568
Authors: Fernanda Vaisman; Denise Momesso; Daniel A Bulzico; Cencita H C N Pessoa; Fernando Dias; Rossana Corbo; Mário Vaisman; R Michael Tuttle Journal: Clin Endocrinol (Oxf) Date: 2012-07 Impact factor: 3.478
Authors: Ji Min Han; Won Gu Kim; Tae Yong Kim; Min Ji Jeon; Jin-Sook Ryu; Dong Eun Song; Suck Joon Hong; Young Kee Shong; Won Bae Kim Journal: Thyroid Date: 2014-01-29 Impact factor: 6.568
Authors: Gregory W Randolph; Quan-Yang Duh; Keith S Heller; Virginia A LiVolsi; Susan J Mandel; David L Steward; Ralph P Tufano; R Michael Tuttle Journal: Thyroid Date: 2012-10-19 Impact factor: 6.568
Authors: Malik E Juweid; Nidal J Rabadi; Mark Tulchinsky; Mohammed Aloqaily; Ahmad Al-Momani; Majd Arabiat; Gassem Abu Ain; Hussam Al Hawari; Munther Al-Momani; Ayman Mismar; Amr Abulaban; Ibrahim Taha; Abdullah Alhouri; Ayman Zayed; Nader Albsoul; Mousa A Al-Abbadi Journal: Endocrine Date: 2021-03-27 Impact factor: 3.633